Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Revatio (sildenafil) Tablets and Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2010

 

Summary View

 

WARNINGS AND PRECAUTIONS

Pulmonary Hypertension Secondary to Sickle Cell Anemia
  • In a small, prematurely terminated study of patients with pulmonary hypertension (PH) secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received Revatio than by those randomized to placebo. The effectiveness of Revatio in PH secondary to sickle cell anemia has not been established.

ADVERSE REACTIONS

  • Vaso-occlusive crisis

 

-
-